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Objectives: We aimed to develop and validate
Kinyarwanda versions of Short-Form Leeds Dyspepsia
Questionnaire (SF-LDQ) and Short-Form Nepean
Dyspepsia Index (SF-NDI) to measure the frequency
and severity of dyspepsia and associated quality-of-life
impact in Rwanda.
Setting: A single, tertiary care centre in Rwanda.
Participants: 200 consecutive Kinyarwanda-speaking
patients referred to endoscopy (100 patients) or
medical outpatients (100 patients).
Interventions: Kinyarwanda versions of the SF-LDQ
and SF-NDI were developed from English versions by
translation, with back translation, crosschecking and
pilot testing. Study participants completed these
questionnaires at enrolment (time 1), and then
completed the surveys again with blinded phone
interviewers 3 days later (time 2). 20 randomly selected
participants, diagnosed with a peptic ulcer on index
endoscopy, completed a third survey by phone at day
30 (time 3), after therapy.
Primary outcome measures: Internal consistency at
time 1 (by Cronbach’s α) and test–retest reliability
between time 1 and time 2 (Spearman’s correlation
coefficient) for translated SF-LDQ and SF-NDI; validity
versus clinical diagnosis (by receiver operating
characteristic (ROC) curve) and responsiveness to
treatment for SF-LDQ (by change in mean score). All
outcomes were measured as per protocol.
Results: Cronbach’s α of the translated SF-LDQ was
0.93, showing high internal consistency. Spearman’s
correlation coefficient comparing time 1 and time 2
was 0.978 (p<0.001), demonstrating high reliability.
Cronbach’s α for the translated SF-NDI was 0.92. A
cut-off score of 16 on the SF-LDQ showed a sensitivity
of 97% and a specificity of 71% for the diagnosis of
dyspepsia, correctly classifying 89% of patients. In the
responsiveness analysis, the mean SF-LDQ score was
reduced from 20.1 prior to treatment to 13.9 after
30 days of treatment (p=0.003).
Conclusions: The Kinyarwanda versions of the SF-
LDQ and SF-NDI were valid, reliable and responsive to
treatment.
INTRODUCTION
Dyspepsia is a constellation of upper gastro-
intestinal symptoms that present a significant
personal, social and financial burden to
patients and healthcare resources world-
wide.1 2 Although no standard, universal def-
inition of dyspepsia adequately characterises
the symptom complex across diverse cultural
and sociodemographic environments; clini-
cians tend to rely on the presence of
chronic, recurrent epigastric pain or discom-
fort as a platform for the diagnosis and man-
agement of patients presenting to primary
and subspecialty healthcare with upper
gastrointestinal symptoms.3
Strengths and limitations of this study
▪ Both dyspepsia symptom severity and
quality-of-life impact measured concurrently in
the same patient population.
▪ Study staff were blinded to time 1 survey results
when administering time 2 surveys.
▪ 100% participant follow-up achieved from time 1
to time 2.
▪ No gold standard comparison available to valid-
ate Short-Form Nepean Dyspepsia Index
(SF-NDI), the dyspepsia quality-of-life tool,
meaning that surrogate markers had to be used.
▪ Survey administration methods differed between
time 1 and time 2: interpersonal interviews and
phone-based interviews.
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The differential diagnosis of non-specific upper gastro-
intestinal symptoms is broad. In the absence of alarm
features, patients with chronic, recurrent upper abdom-
inal pain or discomfort who have yet to undergo add-
itional clinical evaluation are identified with a
preliminary diagnosis of uninvestigated dyspepsia. In a
meta-analysis of cross-sectional surveys reporting the
prevalence of uninvestigated dyspepsia, Ford et al4 report
a global prevalence of 20.8% (n 312 415; range 1.8–
57%; 95% CI 17.8% to 23.9%), identifying significantly
increased prevalence with a broad definition of dyspep-
sia, female gender, use of tobacco or non-steroidal anti-
inflammatory drugs (NSAIDs), and confirmed infection
with Helicobacter pylori.
Esophagogastroduodenoscopy (EGD) remains the
gold standard approach to the investigation of dyspepsia.
Patients with evidence of structural disease on EGD are
considered to have organic dyspepsia; gastro-
oesophageal reflux disease (GERD) and peptic ulcer
disease (PUD) are among the most common endoscopic
diagnoses associated with dyspeptic symptoms world-
wide.5–10 Patients with dyspepsia without evidence of
structural disease despite thorough clinical evaluation
are diagnosed with functional dyspepsia (FD); the
chronic symptom complex of FD is likely multifactorial,
and is often attributed to a combination of visceral
hypersensitivity and upper gastrointestinal dysmotility
that varies with each individual and with time.11 Unlike
dyspepsia of organic origin, FD is not associated with an
increased risk of mortality; however, it is significantly
associated with decrements in health-related quality of
life (HR-QoL).12
Rwanda
Despite growing evidence of significant disease burden,
notably including gastric malignancy, H. pylori infection
and PUD, associated with dyspeptic symptoms in
Rwanda13 and elsewhere in sub-Saharan Africa,8 there
remains a paucity of population-based data characteris-
ing the epidemiology and clinical course of organic and
FD in these locations. Ford et al14 calculated the preva-
lence of dyspepsia in excess of 35% (n 1421; 95% CI
19.2% to 54%) from two surveys15 16 administered in
Nigeria; if these data are representative of the African
continent, the prevalence of uninvestigated dyspepsia in
Africa approaches double that of the global population.
Although EGD is the tool of choice to investigate dys-
pepsia in Rwanda, there are few facilities and trained
providers equipped to provide EGD to Rwandan patients
in this resource-limited healthcare setting. No other clin-
ical tools are currently available to Rwandan healthcare
workers to adequately assess symptom severity, symptom
frequency or HR-QoL of patients with dyspepsia, limiting
the diagnosis, management and investigation of dyspep-
sia in a culturally competent manner. However, as
Rwanda is a small, centralised country that uses a single
traditional language (Kinyarwanda) in addition to
English, it is ideally suited for the use of a patient-
completed questionnaire as a surrogate or adjunct to
EGD in primary and subspecialty healthcare settings.
Tool selection
The Leeds Dyspepsia Questionnaire and the Nepean
Dyspepsia Index, and their short-form equivalents
(SF-LDQ and SF-NDI), are self-reported item-based
questionnaires that were developed in English to quan-
tify dyspeptic symptom severity and frequency and
HR-QoL related to FD, respectively.17 18 Specifically, the
SF-LDQ captures the frequency and severity of upper
abdominal discomfort, heartburn, regurgitation and
nausea over the preceding 2 months. Each item is
assigned a numerical score that is summed into a total
score; scores >14 have been indicative of dyspepsia in
other populations. The SF-NDI evaluates tension/
anxiety, interference with daily activities, disruption of
usual eating/drinking, knowledge of/control over
disease symptoms and interference with work/study with
two-item five-point Likert scales, with a total score calcu-
lated as the mean of the five subscale scores.19
Owing to their simplicity and brevity, there is robust pre-
cedent for translation and validation of the SF-LDQ and
SF-NDI for use in non-English-speaking populations.20
Notably, Mahadeva and colleagues translated and vali-
dated the SF-LDQ21 and SF-NDI22 into Malay and
Malaysian English for use in a multiethnic Asian popula-
tion with dyspepsia, and reported adequate reliability
(internal consistency determined by Cronbach’s α: 0.8 and
0.74; test–retest reliability determined by Spearman’s
coefficient: 0.98), validity (area under the receiver
operating characteristic (ROC) curve: 0.71 and 0.77) and
responsiveness to treatment (mean LDQ score reduced
following treatment with proton pump inhibitor (PPI):
17.0–14.0, p 0.08 in Malay; 18.0–11.0, p 0.008 in Malaysian
English) for both versions of the translated LDQ question-
naire (n 310). For translated versions of the SF-NDI,
Mahadeva et al22 reported adequate internal consistency
and test–retest reliability (Cronbach’s α: 0.83–0.90;
Spearman’s coefficient: 0.83 and 0.90), and approximate
validity with correlation to the 36-Item Short-Form Health
Survey (SF-36), a validated, widely used clinical tool that
measures generic HR-QoL (n 143).
Study objectives
The objective of this study was to develop and validate a
reliable translation of the SF-LDQ and SF-NDI in
Kinyarwanda for use in epidemiological and clinical
applications in primary and subspecialty healthcare set-
tings in Rwanda. This study also assessed the responsive-
ness of the Kinyarwanda version of the SF-LDQ to
treatment in patients diagnosed with dyspepsia.
METHODS
We used a prior Malaysian study validating dyspepsia
tools21 22 as a model for the translation, prospective
cross-sectional survey administration and psychometric
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evaluation of the SF-LDQ and SF-NDI into Kinyarwanda.
The study protocol was reviewed and approved by the
Kigali University Teaching Hospital (KUTH) Ethics
Committee.
Instrument translation
We selected three medically experienced colleagues who
were fluent in both languages to translate the tools from
English into Kinyarwanda. The study author, supervisor
and English–Kinyarwanda translators met to analyse the
language and content of the English tools to guide cul-
turally appropriate translation. Once consensus was
achieved, the translated tools were back-translated from
Kinyarwanda to English by a separate team of three
qualified translators in order to verify that the
Kinyarwanda version of the tools maintained the integ-
rity of the English versions. The study author, supervisor
and translators again met to discuss the language and
content of the back-translated tools. The corrected
Kinyarwanda versions of both tools were then evaluated
by two independent Kinyarwanda linguistic experts, who
made corrections to the translated tools. The final
Kinyarwanda versions of the SF-NDI and SF-LDQ were
then completed by 10 KUTH employees (5 nurses, 3
administrators, 2 service personnel) selected to repre-
sent diverse age (mean age 35 years; range 18–52 years)
and sociodemographic backgrounds (7 female; 7 with
university-level education) in a pilot test of the translated
tool. None of the participants in the pilot administration
of either tool encountered any difficulties with the
Kinyarwanda translation, completing both tools without
assistance. Therefore, no further changes were made to
either tool prior to their use with study participants.
Instrument administration
We recruited adult patients (age >17 years; n 200) who
presented to outpatient medical care at KUTH, a
national referral hospital in Rwanda (n 100) or who
awaited EGD at the same location (n 100). The study
author and a trained research assistant approached
patients in the waiting area of outpatient clinics and the
endoscopic suite, explaining the purpose of the research
and asking if they would like to be considered for enrol-
ment in the study. Patients were excluded from the study
if they reported a history of abdominal surgery, major
medical disease requiring tertiary medical care or
current major psychiatric disease. Patients were also
excluded from the study if they did not adequately speak
and understand Kinyarwanda. Enrolled participants
underwent a process of informed consent, agreeing to
fill out the study tools at that time (time 1) and to be
contacted by phone by study administrators to complete
the tool a second time (time 2). Participants who were
literate in Kinyarwanda were given a printed copy of the
questionnaires to complete themselves at time
1. Trained personnel orally administered the tools to
participants who were not literate in Kinyarwanda at
time 1, and to all participants over the phone at time
2. Study personnel were blinded to time 1 survey results
until all time 2 data were collected.
Data collection
Time 1 data were collected at the time of participant
enrolment at KUTH between November 2014 and
January 2015. Each participant completed a
Kinyarwanda version of the SF-LDQ and SF-NDI, as well
as basic demographic information. Time 2 data were col-
lected 3 days later; participants were contacted by tele-
phone by the study author or a trained research assistant
and asked to orally complete a Kinyarwanda version of
the SF-LDQ and SF-NDI.
In order to test the responsiveness of the SF-LDQ to
treatment, we randomly selected 20 patients who under-
went EGD and were diagnosed with PUD. These patients
completed the SF-LDQ a third time (time 3), following
1 month of oral PPI therapy with or without additional
triple therapy for H. pylori infection.
Data analysis
The translated Kinyarwanda dyspepsia questionnaires
were evaluated by assessing their reliability. Additionally,
the validity and responsiveness of the SF-LDQ were
assessed. We used SPSS V.16.0 and Excel to compute the
statistical parameters reported in this study. Participants
who did not complete the time 1 and time 2 surveys in
full were excluded from analysis.
Specifically, the internal consistency and test–retest
reliability of the translated SF-LDQ and SF-NDI were
determined by calculating Cronbach’s α for time 1 and
time 2 scores and Spearman’s correlation coefficient
between time 1 and time 2 scores, respectively. The val-
idity of the SF-LDQ was determined against the gold
standard of clinical diagnosis using ROC curves. There
is no gold standard for the measurement of HR-QoL;
therefore, the validity of the translated SF-NDI was esti-
mated first against SF-LDQ scores collected at time 1
during this study using ROC curves, and then using the
Mann-Whitney U test to establish known groups’ con-
struct validity of the total and five subscale scores of the
SF-NDI relative to the severity (increased symptom sever-
ity defined as SF-LDQ≥15) of dyspeptic symptoms.22 We
assessed the responsiveness of the SF-LDQ using
Wilcoxon rank matched-pair testing by comparing the
time 1 and post-treatment scores of 20 patients who were
diagnosed with PUD on EGD, underwent 30 days of PPI
therapy and completed the tool a third time.
RESULTS
The final Kinyarwanda-translated versions of the SF-LDQ
and SF-NDI tools are presented as online supplementary
appendices 1 and 2.
A total of 200 study participants were enrolled
between November 2014 and January 2015. The mean
age of enrolled patients was 41 years. A majority of
patients in the overall cohort were diagnosed with
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dyspepsia by a clinician (true dyspepsia prevalence
among study participants 69%), including all of the
patients awaiting EGD. Most patients were residents of
Kigali (61%) and 62% were female (see table 1).
Short-Form Leeds Dyspepsia Questionnaire
The response rates for the SF-LDQ and SF-NDI at time 1
and time 2 were 100%. Cronbach’s α was calculated at
time 1 and time 2 to assess the internal consistency of
the translated SF-LDQ, revealing a value of 0.93 at time
1 and 0.92 at time 2. The Spearman’s correlation coeffi-
cient between time 1 and time 2 scores on the SF-LDQ
was 0.978. Response frequencies for each item on the
SF-LDQ are shown in table 2.
The summed total score of the SF-LDQ at time 1 was
compared to the gold standard of clinical diagnosis by
the treating physician, using an ROC curve (figure 1).
The point along the ROC curve that correctly classified
most participants was chosen as the SF-LDQ cut-off
score for the diagnosis of dyspepsia. This SF-LDQ cut-off
score of 16 showed a sensitivity of 97% and a specificity
of 71% for the diagnosis of dyspepsia, correctly classify-
ing 89% of study participants (κ coefficient 0.75).
Among the 20 patients with PUD who received PPI
therapy and were again interviewed at time 3, the mean
SF-LDQ score changed from 20.1 prior to treatment
(time 1) to 13.9 after 1 month of therapy (time 3), with
a p value of 0.003 by Wilcoxon rank matched-pair
testing.
Short-Form Nepean Dyspepsia Index
Cronbach’s α for the SF-NDI was 0.96 at time 1 and 0.95
at time 2. The Spearman’s correlation coefficient
between time 1 and time 2 scores on the SF-NDI was
0.89.
The validity of the SF-NDI was first estimated by com-
parison of the per-patient total scores on the SF-NDI
and SF-LDQ, using ROC curves plotted against clinical
diagnosis (figure 2). The area under each curve was
similar (0.91 for SF-LDQ vs 0.89 for SF-NDI), and no
statistical difference was apparent between the two
curves (p=0.35).
Known groups’ construct validity of the total and sub-
scale scores of the Kinyarwanda version of the SF-NDI
was established relative to the severity of dyspeptic symp-
toms using the Mann–Whitney U test. For all five sub-
scale scores and the total score of the SF-NDI, there was
significant (p<0.001) compromise of HR-QoL for
patients with severe relative to patients with mild dyspep-
tic symptoms (table 3).
DISCUSSION
This study demonstrates that tools developed for the
study of dyspepsia prevalence and its impact on HR-QoL
in Western populations can be successfully adapted for
use in an African language and cultural context.
Obtained results indicate that Kinyarwanda versions of
the SF-LDQ and SF-NDI are reliable and internally con-
sistent and that the SF-LDQ displays a high correlation
with African physicians’ clinical diagnoses, with 89% of
patients correctly classified by an SF-LDQ>16 (area
under the ROC curve 0.91). While objective proof of the
quality-of-life impact measured by the SF-NDI was more
difficult to obtain, secondary markers suggest a high cor-
relation between SF-NDI and SF-LDQ scores, as well as
high internal consistency and reliability for the SF-NDI.
Finally, the SF-LDQ was responsive to changes with treat-
ment in patients likely to respond to acid suppression,
with a clinically and statistically significant fall in both
scores in patients with clinically diagnosed PUD follow-
ing initiation of a PPI.
The strengths of this study lie in clear and rigorous
validation methodology applied to a sub-Saharan linguis-
tic and cultural context with significant
dyspepsia-associated disease burden but without clinical
precedent for evaluative tools available to treating physi-
cians. This study’s administration of both tools in
written, oral and phone-based forms realistically reflects
the modes of communication that are routinely and
necessarily employed for clinical and research purposes
Table 1 Demographic characteristics of study population
Characteristic Number (%)
Dyspepsia 137 (68)






























No children 62 (31)
Residency refers to province of residence.
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in Rwanda, ensuring that clinicians can confidently
employ these tools without concern for compromised
results. Both tools were chosen for their simplicity and
ease of use, further reducing survey length and complex-
ity, barriers which can otherwise prove insurmountable
in real-world African settings, where clinical demands
often compete with research for the limited healthcare
worker resources available. Additionally, the simultan-
eous evaluation of dyspeptic symptom prevalence and
HR-QoL enables this study to demonstrate for the first
time that these domains are closely correlated in an
African population, a link that bears important clinical
and healthcare policy implications as Rwanda adapts to
treat this patient population.
Although this is the first validation of the SF-LDQ and
SF-NDI in Africa, similar studies have been performed in
Malaysia and China;21 23 together with the initial valid-
ation studies of these tools in Western populations;17–19 24
Table 2 Time 1 response frequencies for the SF-LDQ
Frequency (%) Severity (%)
Indigestion
Not at all 38 (19) 44 (22)
Less than once a month 14 (7) 14 (7)
Between once a month and once a week 23 (11.5) 21 (10.5)
Between once a week and once a day 42 (21) 44 (22)
Once a day and more 83 (41.5) 77 (38.5)
Heartburn
Not at all 65 (32.5) 74 (37)
Less than once a month 18 (9) 19 (9.5)
Between once a month and once a week 28 (14) 25 (12.5)
Between once a week and once a day 37 (18.5) 34 (17)
Once a day or more 52 (26) 48 (24)
Regurgitation
Not at all 80 (40) 80 (40)
Less than once a month 22 (11) 25 (12.5)
Between once a month and once a week 25 (12.5) 27 (13.5)
Between once a week and once a day 38 (19) 36 (18)
Once a day and more 35 (17.5) 32 (16)
Nausea
Not at all 69 (34.5) 73 (36.5)
Less than once a month 15 (7.5) 20 (20)
Between once a month and once a week 24 (12) 24 (12)
Between once a week and once a day 40 (20) 35 (17.5)
Once a day or more 52 (26) 48 (24)
SF-LDQ, Short-Form Leeds Dyspepsia Questionnaire.
Figure 1 ROC curve for SF-LDQ total score at time 1
against clinical diagnosis. ROC, receiver operating
characteristic; SF-LDQ, Short-Form Leeds Dyspepsia
Questionnaire.
Figure 2 ROC curves for SF-NDI and SF-LDQ at time 1
against clinical diagnosis. ROC, receiver operating
characteristic; SF-LDQ, Short-Form Leeds Dyspepsia
Questionnaire; SF-NDI, Short-Form Nepean Dyspepsia Index;
QoL, quality of life.
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these global results serve as a benchmark for the use of
long-form and short-form versions of the LDQ and NDI
in multiple languages and varied populations.
Specifically, LDQ translations to Malay, Malaysian
English and Mandarin21 23 performed similar to the
current study in terms of reliability (Spearman’s coeffi-
cient 0.78–0.98), with a range of internal consistency
(Cronbach α 0.74–0.80) lower than results reported for
this study population. Critically, LDQ results in historical
studies of primary and secondary care populations were
less valid (when compared with clinical diagnoses) than
those obtained in this study (area under the ROC curves
ranging from 0.71 to 0.84), save for a single Italian
version of the SF-NDI (Cronbach’s α 0.90, Pearson’s
correlation coefficient 0.92, sensitivity 80% and
specificity 82%).25
Therefore, within the context of these geographically
and demographically comparable validation studies, the
results of this initiative to develop tools to measure the
prevalence of dyspepsia and its impact on HR-QoL in
sub-Saharan Africa impress with their robust validity. This
relative success may be attributed to a number of observa-
tions, including differences in patient presentation, as
African patients tend to present later in the course of
other diseases,26 differences in patient population, as this
study enrolled patients at a tertiary care centre, or differ-
ences in the cultural expression of dyspeptic symptoms.27
It is also possible that the tools developed by this study
are more culturally intelligible than those deployed in
prior research settings, given the meticulous, multidiscip-
linary methods by which they were translated.
All research initiatives are subject to limitations. In this
study, no gold standard for dyspepsia-related quality of
life has been developed in Kinyarwanda; therefore, the
validity of the SF-NDI was evaluated with surrogate
SF-LDQ scores and contemporaneous clinical diagnoses.
As this study focused exclusively on patients seeking
medical care at a tertiary healthcare centre, it is possible
that the Kinyarwanda version of the SF-LDQ might prove
less discriminatory in other populations; however, the
wide range of SF-LDQ and SF-NDI scores and the signifi-
cant prevalence of incidental dyspepsia in the medical
outpatient population (which likely resembles ‘primary’
dyspepsia) suggest a diversity of patient illness experience
that is reassuring. Finally, the initial administration of
these tools (verbal or written) depended on the literacy
of each enrolled patient; all patients completed the
surveys by telephone on readministration. Although this
heterogeneity could potentially have reduced the test–
retest reliability of these tools, in fact reliability remained
encouragingly high in our final study analysis. Further
investigation of dyspepsia in African populations, with
attendant translations of these tools into other African
languages, will prove instructive areas for future research.
CONCLUSION
The Kinyarwanda versions of the SF-LDQ and SF-NDI
developed by this study proved reliable and valid, par-
ticularly when compared to the gold standard of clinical
diagnosis. These tools are recommended for use in clin-
ical and research initiatives involving the prevalence of
dyspepsia and its impact on HR-QoL in Kinyarwanda-
speaking patients of sub-Saharan Africa.
Author affiliations
1College of Medicine and Health Sciences, University of Rwanda, Huye,
Rwanda
2Kigali University Teaching Hospital, Kigali, Rwanda
3Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire,
USA
4Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA
5Butare University Teaching Hospital, Huye, Rwanda
Acknowledgements The authors thank Professor Nick Talley and Professor
Brendan Delaney for kind permission to translate the SF-NDI and SF-LDQ
tools.
Contributors TW conceived the study. AN, VD and TW designed the study.
AN and VD carried out and supervised the interviews. AN, VD, KE, SB and
TW interpreted the data. AN, KE, SB and TW drafted the manuscript. AN, VD,
KE, SB and TW critically revised the manuscript for intellectual content. All
authors read and approved the final manuscript. TW and AN are guarantors of
the paper.
Funding This study was partially funded by the Rwandan Ministry of Health,
via a Masters of Medicine (Internal Medicine) Research Grant. The views
expressed are those of the authors and not of the Rwandan Ministry of
Health.






(n 152) p Value‡
Tension (median; range) 2 (2–6) 5 (2–10) <0.001
Interference (median; range) 2 (2–4) 6 (2–10) <0.001
Eating/drinking (median; range) 3 (2–5) 6 (2–10) <0.001
Knowledge/control (median; range) 2 (2–4) 3 (2–10) 0.001
Work/study (median; range) 2 (2–6) 6 (2–10) <0.001
Total (median; range) 25 (20–44) 56 (20–92) <0.001
*Mild SF-LDQ<15; severe SF-LDQ≥15.
†Patients who reported ‘non-applicable’ on the SF-NDI were excluded from this analysis.
‡Mann–Whitney U test.
SF-LDQ, Short-Form Leeds Dyspepsia Questionnaire; SF-NDI, Short-Form Nepean Dyspepsia Index.
6 Nkurunziza A, et al. BMJ Open 2016;6:e011018. doi:10.1136/bmjopen-2015-011018
Open Access
Competing interests None declared.
Patient consent Obtained.
Ethics approval The study was approved by the Kigali University Teaching
Hospital Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement A database containing deidentified patient-level data
for all study participants’ response to administered questionnaires at all time
points is available from the corresponding author upon request.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Brook RA, Kleinman NL, Choung RS, et al. Functional dyspepsia
impacts absenteeism and direct and indirect costs.
Clin Gastroenterol Hepatol 2010;8:498–503.
2. Lacy BE, Weiser KT, Kennedy AT, et al. Functional dyspepsia: the
economic impact to patients. Aliment Pharmacol Ther
2013;38:170–7.
3. Ford AC, Bercik P, Morgan DG, et al. The Rome III criteria for the
diagnosis of functional dyspepsia in secondary care are not superior
to previous definitions. Gastroenterol 2014;146:932–40.
4. Ford AC, Marwaha A, Sood R, et al. Global prevalence of, and risk
factors for, uninvestigated dyspepsia: a meta-analysis. Gut 2015
Jul;64:1049–57.
5. Mahadeva S, Goh KL. Clinically significant endoscopic findings in a
multi-ethnic population with uninvestigated dyspepsia. Dig Dis Sci
2012;57:3205–12.
6. Samaila A, Okeke E, Malu A. Endoscopic findings and clinical
predictors of organic disease among patients with dyspepsia in Jos,
Nigeria. Nig J Gastroenterol Hepatol 2011;3:39–46.
7. Faintuch JJ, Silva FM, Navarro-Rodriguez T, et al. Endoscopic
findings in uninvestigated dyspepsia. BMC Gastroenterol
2014;14:19.
8. Ayana SM, Swai B, Maro VP, et al. Upper gastrointestinal
endoscopic findings and prevalence of Helicobacter pylori infection
among adult patients with dyspepsia in northern Tanzania. Tanzan J
Health Res 2014;16:16–22.
9. Vasiliou C, Xiromeritou V, Kafiri G, et al. Endoscopic and histological
findings and Helicobacter pylori status in patients with reflux and/or
dyspeptic symptoms: a recent Greek cohort study. Gastroenterol
Nurs 2014;37:431–8.
10. Afihene MK, Denyer M, Amuasi JH, et al. Prevalence of
Helicobacter pylori and Endoscopic findings among Dyspeptics in
Kumasi, Ghana. Open Sci J Clin Med 2014;2:63.
11. Lee KJ, Kindt S, Tack J. Pathophysiology of functional dyspepsia.
Best Pract Res Clin Gastroenterol 2004;18:707–16.
12. Aro P, Talley NJ, Agréus L, et al. Functional dyspepsia impairs
quality of life in the adult population. Aliment Pharmacol Ther
2011;33:1215–24.
13. Walker TD, Karemera M, Ngabonziza F, et al. Helicobacter pylori
status and associated gastroscopic diagnoses in a tertiary hospital
endoscopy population in Rwanda. Trans R Soc Trop Med Hyg 2014
May;108:305–7.
14. Ford AC, Talley NJ. Epidemiology of dyspepsia. In: Talley NJ, Locke
GR, Moayyedi P, West JJ, Ford AC, Saito YA, eds. GI epidemiology:
diseases and clinical methodology. 2nd edn. Chichester: Wiley-
Blackwell, 2014:158–71.
15. Holcombe C, Omotara BA, Padonu MK, et al. The prevalence of
symptoms of dyspepsia in north eastern Nigeria. A random
community based survey. Trop Geogr Med 1991;43:209–14.
16. Ihezue CH, Oluwole FS, Onuminya JE, et al. Dyspepsias among the
highlanders of Nigeria: an epidemiological survey. Afr J Med Med
Sci 1996;25:23–9.
17. Moayyedi P, Duffett S, Braunholtz D, et al. The Leeds Dyspepsia
Questionnaire: a valid tool for measuring the presence and severity
of dyspepsia. Aliment Pharmacol Ther 1998;12:1257–62.
18. Talley NJ, Haque M, Wyeth JW, et al. Development of a new
dyspepsia impact scale: the Nepean Dyspepsia Index. Aliment
Pharmacol Ther 1999;13:225–36.
19. Talley NJ, Verlinden M, Jones M. Quality of life in functional
dyspepsia: responsiveness of the Nepean Dyspepsia Index and
development of a new 10-item short form. Aliment Pharmacol Ther
2001;15:207–16.
20. Anastasiou F, Antonakis N, Chaireti G, et al. Identifying dyspepsia in
the Greek population: translation and validation of a questionnaire.
BMC Public Health 2006;6:56.
21. Mahadeva S, Chan WK, Mohazmi M, et al. Validation study of the
Leeds Dyspepsia Questionnaire in a multi-ethnic Asian population.
J Gastroenterol Hepatol 2011;26:1669–76.
22. Mahadeva S, Wee HL, Goh KL, et al. Quality of life in South East
Asian patients who consult for dyspepsia: validation of the short
form Nepean Dyspepsia Index. Health Qual Life Outcomes
2009;7:45.
23. Leow HR, Ching SM, Sujarita R, et al. Mandarin version of the
Leeds Dyspepsia Questionnaire: a valid instrument for assessing
symptoms in Asians. J Dig Dis 2014;15:591–6.
24. Fraser A, Delaney BC, Ford AC, et al. The short-form Leeds
Dyspepsia Questionnaire validation study. Aliment Pharmacol Ther
2007;25:477–86.
25. Gatta L, Moayyedi P, Tosetti C, et al. A validation study of the Italian
Short-Form Leeds Dyspepsia Questionnaire. Intern Emerg Med
2010;5:501–6.
26. Kigozi IM, Dobkin LM, Martin JN, et al. Late-disease stage at
presentation to an HIV clinic in the era of free antiretroviral therapy
in Sub-Saharan Africa. J Acquir Immune Defic Syndr
2009;52:280–9.
27. Yap P, Mahadeva S, Goh KL. The influence of cultural habits on
the changing pattern of functional dyspepsia. Dig Dis
2014;32:217–21.
Nkurunziza A, et al. BMJ Open 2016;6:e011018. doi:10.1136/bmjopen-2015-011018 7
Open Access
